This time we have solanezumab (monoclonal failure against AD):
After years of anticipation and growing skepticism, Eli Lilly this morning disclosed that an Alzheimer’s medication failed to meet the primary endpoints, both cognitive and functional, in a pair of Phase III double-blind, placebo-controlled trials in patients with mild-to-moderate Alzheimer’s disease. Although disappointing, the outcome was actually mixed, but may still renew questions about the future for Lilly as it grapples with its commitment to Alzheimer’s research.
And BMS-986094 (which targets polymerase, an enzyme essential for the replication of the hepatitis C virus):
(Reuters) - Bristol-Myers Squibb Co (BMY) said it would record a $1.8 billion charge related to the discontinuation of its much-anticipated hepatitis C drug that was dropped after a patient died of heart failure.
The company will recognize the charge in the third quarter of 2012, it said in a regulatory filing on Friday. It does not expect the charge to result in future cash expenses.
The pharmaceutical company said on Thursday it would drop development of the drug, called BMS-986094, after a patient who was treated with the drug in a mid-stage trial died of heart failure and several others had to be hospitalized.
Bristol had voluntarily stopped the mid-stage trial earlier this month.
The drug, which was acquired by Bristol through its $2.5 billion purchase of Inhibitex Inc, belongs to a promising new class of hepatitis C drugs known as nucleotide polymerase inhibitors.
What targeted drug will fail next?
No comments:
Post a Comment